Banner
targets (1)
for drugs
Identification
Name Calcium Acetate
Accession Number DB00258 (APRD00839)
Type small molecule
Groups approved
Description

The chemical compound calcium acetate is the calcium salt of acetic acid. An older name is acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. [Wikipedia]
Structure Thumb
Download: MOL | SDF | SMILES | InChI
Display: 2D Structure | 3D Structure
Synonyms
  • Acetic acid, calcium salt
  • Brown acetate
  • Brown acetate of lime
  • Calcium acetate hydrate
  • Calcium acetate monohydrate
  • Calcium diacetate
  • Gray acetate
  • Gray acetate of lime
  • Grey acetate
  • Lime acetate
  • Lime pyrolignite
  • Procalamine
  • Pyrolignite of lime
  • Vinegar salts
Brand names
  • Calac
  • Niacet calcium acetate tech
  • PhosLo
  • PhosLo Gelcaps
  • Sorbo-calcian
  • Sorbo-calcion
  • Teltozan
Brand name mixtures
  • Anti Stress (Calcium Acetate + Folic Acid + Magnesium Chloride + Menadione Sodium Bisulfite + Potassium (Potassium Bicarbonate) + Pyridoxine Hydrochloride + Sodium Acetate + Sodium Chloride + Vitamin a + Vitamin B12 + Vitamin C + Vitamin D3 + Vitamin E)
  • Electrolyte Booster- Soluble Powder (Biotin + Calcium Acetate + Folic Acid + Magnesium Chloride + Menadione Sodium Bisulfite + Potassium Chloride + Sodium Acetate + Sodium Bicarbonate + Sodium Chloride + Sodium Diacetate + Vitamin a (Vitamin a Acetate) + Vitamin B12 + Vitamin B2 (Riboflavin) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Ascorbic Acid) + Vitamin D3 (Cholecalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate))
  • Electrolytes Plus (Calcium Acetate + Calcium D-Pantothenate + Choline Bitartrate + Folic Acid + Magnesium Chloride + Menadione (Menadione Sodium Bisulfite) + Nicotinamide + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a Acetate + Vitamin B12 + Vitamin B2 + Vitamin D3 + Vitamin E)
  • Electrovite (Calcium Acetate + Calcium Chloride + Folic Acid + Magnesium Acetate + Menadione Sodium Bisulfite + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a + Vitamin B12 + Vitamin B6 + Vitamin C + Vitamin D3 + Vitamin E)
  • Hyperlyte (Multi-Electrolyte Concentrate) (Calcium Acetate + Magnesium Acetate + Potassium Acetate + Potassium Chloride + Sodium Acetate + Sodium Gluconate)
  • Jugelect Tab (Calcium Acetate + Calcium Citrate + Magnesium Acetate + Magnesium Citrate + Potassium Chloride + Sodium Chloride)
  • Lypholyte - Liq Iv (Calcium Acetate + Magnesium Acetate + Potassium Acetate + Potassium Chloride + Sodium Acetate + Sodium Gluconate)
  • Lypholyte Multi-Electrolyte Conc Inj (Calcium Acetate + Magnesium Acetate + Potassium Acetate + Potassium Chloride + Sodium Acetate + Sodium Gluconate)
  • Medi-Kool Pak (Aluminum Sulfate + Arnica + Boric Acid + Calcium Acetate + Camphor + Menthol + Methyl Salicylate + Tannic Acid)
  • Mineralytes Plus (Calcium Acetate + Calcium D-Pantothenate + Choline Bitartrate + Dl-Alpha Tocopheryl Acetate + Folic Acid + Magnesium Chloride + Menadione (Menadione Sodium Bisulfite) + Nicotinamide + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a Acetate + Vitamin B12 + Vitamin B2 + Vitamin D3)
  • Parvit Ii (Calcium Acetate + Folic Acid + Magnesium Chloride + Menadione Sodium Bisulfite (Vitamin K3) + Potassium (Potassium Bicarbonate) + Sodium (Sodium Acetate, Sodium Diacetate, Sodium Chloride) + Vitamin a + Vitamin B12 + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Vitamin C) + Vitamin D3 + Vitamin E)
  • Renodoron - Tablet (Calcium Acetate + Silicon Dioxide)
  • Super Electrolyte - Pwr Orl (Calcium Acetate + Calcium D-Pantothenate + Choline Bitartrate + Folic Acid + Magnesium Chloride + Menadione (Menadione Sodium Bisulfite) + Nicotinamide + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a (Vitamin a Acetate) + Vitamin B12 + Vitamin B2 (Riboflavin) + Vitamin D3 (Cholecalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate))
  • Thc Complex #19 (Aconite + Antimony Trisulfide + Arnica Montana + Beechwood Creosote + Belladonna + Calcium Acetate + Calcium Fluoride + Calcium Phosphate (Tribasic) + Citrullus Colocynthis + Coffee + Delphinium Staphisagria + Ferrum Phosphoricum + German Chamomile + Magnesium Phosphate Dibasic + Plantago Major + Podophyllum + Silicon Dioxide)
  • Thc Complex #66 (Aconite + Barium Carbonate + Belladonna + Bryonia + Calcium Acetate + Oyster Shells + Phytolacca Decandra + Poison Ivy + Sulfur)
  • Tym-Plex (Calcium Acetate + Calcium Sulfide Crude + Echinacea Angustifolia + Phosphoric Acid + Phosphorus)
  • Vitadol Plus Soluble Powder (Calcium Acetate + Folic Acid + Magnesium Chloride + Menadione Sodium Bisulfite + Potassium Bicarbonate + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a + Vitamin B12 + Vitamin B6 + Vitamin C + Vitamin D3 + Vitamin E)
Categories
  • Antihyperphosphatemics
  • Chelating Agents
CAS number 62-54-4
Weight Average: 158.166
Monoisotopic: 157.989199835
Chemical Formula C4H6CaO4
InChI Key InChIKey=VSGNNIFQASZAOI-UHFFFAOYSA-L
InChI
InChI=1S/2C2H4O2.Ca/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2
Plain Text
IUPAC Name
calcium bis(acetate)
SMILES
[Ca++].CC([O-])=O.CC([O-])=O
Plain Text
Mass Spec Not Available
Taxonomy
Kingdom Organic
Classes
  • Acetates
Substructures
  • Anions
  • Acetates
  • Carboxylic Acids and Derivatives
  • Cations
Pharmacology
Indication Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.
Pharmacodynamics Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.
Mechanism of action Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.
Absorption 40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.
Volume of distribution Not Available
Protein binding Not Available
Metabolism
Route of elimination Calcium acetate when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces.
Half life Not Available
Clearance Not Available
Toxicity Oral, rat: LD50 = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).
Affected organisms
  • Humans and other mammals
Pathways Not Available
Pharmacoeconomics
Manufacturers
  • Roxane laboratories inc
  • Fresenius medical care north america
  • Cypress pharmaceutical inc
Packagers
Dosage forms
Form Route Strength
Liquid Oral
Solution / drops Oral
Tablet Oral
Prices
Unit description Cost Unit
PhosLo 667 mg capsule 1.05 USD capsule
Phoslo 667 mg tablet 0.41 USD tablet
Patents
Country Patent Number Approved Expires
United States 6576665 2001-04-03 2021-04-03
Properties
State solid
Melting point > 160 oC
Experimental Properties Not Available
Predicted Properties
Property Value Source
water solubility 1.47e+02 g/l ALOGPS
logP 0.24 ALOGPS
logP -0.22 ChemAxon Molconvert
logS -0.03 ALOGPS
pKa ChemAxon Molconvert
hydrogen acceptor count 2 ChemAxon Molconvert
hydrogen donor count 0 ChemAxon Molconvert
polar surface area 40.13 ChemAxon Molconvert
rotatable bond count 0 ChemAxon Molconvert
refractivity 23.48 ChemAxon Molconvert
polarizability 4.96 ChemAxon Molconvert
References
Synthesis Reference Not Available
General Reference Not Available
External Links
Resource Link
KEGG Drug D00931 Link_out
PubChem Compound 6116 Link_out
PubChem Substance 46507985 Link_out
ChemSpider 5890 Link_out
PharmGKB PA448724 Link_out
Drug Product Database 1982591 Link_out
Drugs.com http://www.drugs.com/cdi/calcium-acetate.html Link_out
Wikipedia http://en.wikipedia.org/wiki/Calcium_Acetate Link_out
ATC Codes
  • A12AA12
AHFS Codes
  • 40:18.19
  • 92:02.00*
PDB Entries Not Available
FDA label show (25.6 KB)
MSDS show (72.9 KB)
Interactions
Drug Interactions Not Available
Food Interactions Not Available
Targets

1. Phosphate

Pharmacological action: yes
Actions: binder

References:
  1. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. 1989 Oct;36(4):690-5. Pubmed
  2. Nolan CR, Qunibi WY: Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Curr Opin Nephrol Hypertens. 2003 Jul;12(4):373-9. Pubmed
  3. Nolan CR, Qunibi WY: Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney Int Suppl. 2005 Jun;(95):S13-20. Pubmed
  4. Nolan CR: Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines. Kidney Int Suppl. 2005 Jul;(96):S7-14. Pubmed
Comments
Drug created on June 13, 2005 07:24 / Updated on December 21, 2010 15:32

This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community.